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A B S T R A C T
Retinitis pigmentosa (RP) encompasses a group of inherited retinal dystrophies characterized by the primary
degeneration of rod and cone photoreceptors. RP is a leading cause of visual disability, with a worldwide pre-
valence of 1:4000. Although the majority of RP cases are non-syndromic, 20–30% of patients with RP also have
an associated non-ocular condition. RP typically manifests with night blindness in adolescence, followed by
concentric visual ﬁeld loss, reﬂecting the principal dysfunction of rod photoreceptors; central vision loss occurs
later in life due to cone dysfunction. Photoreceptor function measured with an electroretinogram is markedly
reduced or even absent. Optical coherence tomography (OCT) and fundus autoﬂuorescence (FAF) imaging show
a progressive loss of outer retinal layers and altered lipofuscin distribution in a characteristic pattern. Over the
past three decades, a vast number of disease-causing variants in more than 80 genes have been associated with
non-syndromic RP. The wide heterogeneity of RP makes it challenging to describe the clinical ﬁndings and
pathogenesis. In this review, we provide a comprehensive overview of the clinical characteristics of RP speciﬁc
to genetically deﬁned patient subsets. We supply a unique atlas with color fundus photographs of most RP
subtypes, and we discuss the relevant considerations with respect to diﬀerential diagnoses. In addition, we
discuss the genes involved in the pathogenesis of RP, as well as the retinal processes that are aﬀected by pa-
thogenic mutations in these genes. Finally, we review management strategies for patients with RP, including
counseling, visual rehabilitation, and current and emerging therapeutic options.
1. Introduction
Retinitis pigmentosa (RP) is a major cause of visual disability and
blindness, aﬀecting more than 1.5 million patients worldwide. RP is the
most common inherited retinal dystrophy (IRD), with a worldwide
prevalence of approximately 1:4000 (Pagon, 1988), although reports
vary from 1:9000 (Na et al., 2017) to as high as 1:750 (Nangia et al.,
2012), depending on the geographic location. The term “retinitis pig-
mentosa” was ﬁrst coined by the famous Dutch ophthalmologist F.C.
Donders in 1857 (Donders, 1857), although his colleague A.C. van Trigt
provided the ﬁrst description of RP viewed through an ophthalmoscope
four years earlier (Van Trigt, 1853). Even in those early days, certain
forms of retinal degenerations had already been reported. For example,
in 1744 R.F. Ovelgün described a form of familial night blindness clo-
sely resembling RP (Ovelgün, 1744). In the early 19th century, both M.
Schon and F.A. von Ammon reported patients with poor vision and
pigmented retinal lesions (Schon, 1828; Von Ammon, 1838).
RP encompasses a group of progressive IRDs characterized by the
primary degeneration of rod photoreceptors, followed by the loss of
cone photoreceptors. The initial symptom is reduced night vision,
which is followed by a progressive loss of the visual ﬁeld in a concentric
pattern. Function at the macula is usually relatively well preserved until
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later stages of the disease. Fundus abnormalities typically include bone
spicule pigmentation predominantly in the periphery and/or mid-per-
iphery, attenuation of retinal vessels, and a waxy pallor of the optic
nerve head. An electroretinogram can help in the diagnosis and reveals
the characteristic loss of photoreceptor function, primarily among rod
photoreceptors rather than cones in early stages of the disease.
RP is clinically distinct from other IRDs, including IRDs that man-
ifest at birth or within the ﬁrst few months of life (e.g., Leber congenital
amaurosis, or LCA), dystrophies in which cone degeneration precedes
rod degeneration (e.g., cone-rod dystrophy), macular dystrophies, and
disorders that are generally not progressive such as achromatopsia and
congenital stationary night blindness (CSNB). In addition, 20–30% of
patients with RP present with a syndromic form of RP associated with
extra-ocular abnormalities. Together, all of these disorders form a
continuum of retinal dystrophies with partially overlapping clinical
and/or genetic ﬁndings (Fig. 1). This overlap can complicate the clas-
siﬁcation of an individual IRD and is subject to discussion. Moreover,
few therapeutic options are currently available in daily clinical practice.
Therefore, the practitioner's focus should be to provide the patient with
the best possible information regarding the expected clinical course and
inheritance pattern. In this respect, developing a classiﬁcation system
that combines the clinical diagnosis with the underlying genetic factors
can provide valuable prognostic information regarding the rate of
progression and long-term outcome.
The wide heterogeneity among RP patients is best illustrated by the
large number of genetic defects associated with RP. In 1990, Dryja et al.
reported the ﬁrst identiﬁed gene involved in autosomal dominant RP:
the rhodopsin (RHO) gene (Dryja et al., 1990). Since then, mutations in
more than 80 genes have been implicated in non-syndromic RP (Daiger
et al., 2016), and each year new genes are added to this list. Each of
these genes corresponds to a gene-speciﬁc subtype of RP with a speciﬁc
age of onset, visual impairment, retinal appearance, and/or rate of
progression. Moreover, several factors can vary widely within each of
these gene-speciﬁc subtypes, even between aﬀected family members,
suggesting the presence of unidentiﬁed genetic and/or environmental
factors that can inﬂuence the RP phenotype.
Information regarding the clinical course of various RP subtypes is
spread across numerous reports that often describe only limited num-
bers of patients. In this review, we provide a comprehensive overview
of the clinical features associated with the various genetic subtypes of
non-syndromic RP. A related—yet equally complicated—subject is the
functional role of the many proteins encoded by their respective RP
genes. To better appreciate the eﬀect of mutations in RP genes, we also
discuss the role of these proteins in the structure and function of the
retina. Finally, we discuss the current therapeutic options and future
perspectives for non-syndromic RP.
2. Clinical ﬁndings in RP
RP is characterized by the progressive degeneration of photo-
receptors and retinal pigment epithelium (RPE), leading to night
blindness, tunnel vision, and a gradual reduction of central vision.
However, the clinical ﬁndings in RP vary widely due to the large
number of genes involved, each of which can have several alleles. In
this chapter, we discuss the clinical features that are generally con-
sidered to be characteristic of RP. A comprehensive overview of the
features speciﬁc to the various genetic subtypes of RP is provided in
Chapter 4.
2.1. Age of onset and rate of progression
In the “classic” presentation of RP, diﬃculty with dark adaptation
begins in adolescence, and visual loss in the mid-peripheral ﬁeld be-
comes apparent in young adulthood. However, the age at onset among
patients with RP varies widely; thus, some patients develop sympto-
matic visual loss in early childhood, whereas others can remain
Fig. 1. Venn diagram summarizing the genetic overlap be-
tween RP and other inherited retinal dystrophies. Each circle
represents a speciﬁc clinical diagnosis. The gene names listed
in the overlapping areas indicate that mutations in these
genes can lead to diﬀerent phenotypes. Genes marked with an
asterisk are candidate genes for non-syndromic RP.;
Abbreviations: CRD: cone-rod dystrophy, CSNB: congenital
stationary night blindness, ESCS: enhanced S-cone syndrome,
LCA: Leber congenital amaurosis, MD: macular dystrophy,
RP: retinitis pigmentosa.
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relatively asymptomatic until mid-adulthood. The exact age of onset is
often diﬃcult to determine, as many patients—particularly chil-
dren—are able to compensate for peripheral visual loss. In addition,
diﬃculties with dark adaptation can remain unnoticed by the patient
due to our artiﬁcially illuminated nighttime environment.
In general, RP subtypes that manifest early in life tend to progress
more rapidly. Moreover, the severity of the disease is correlated with
the disease's Mendelian pattern of inheritance. In general, patients with
X-linked RP (5–15% of RP patients) have a more severe disease course
compared to patients with autosomal recessive RP (50–60% of RP pa-
tients), whereas patients with an autosomal dominant form of RP
(30–40% of RP patients) (Bunker et al., 1984; Novak-Lauŝ et al., 2002)
have the best long-term prognosis with respect to retaining central vi-
sion (Grover et al., 1996; Hamel, 2006).
2.2. Symptoms
The initial symptoms of RP include night blindness (nyctalopia) and
diﬃculty with dark adaptation. In some cases, RP can also present with
loss of the mid-peripheral visual ﬁeld, although this is rarely reported as
an early symptom. The central retina remains relatively preserved until
the ﬁnal stages of the disease, although anatomical abnormalities in the
central retina can appear early in the course of the disease. Eventually,
and typically when the patient reaches middle age, central cone de-
generation leads to a decline in visual acuity. Most patients with RP
retain the ability to perceive light due to residual macular function and/
or the presence of a preserved peripheral temporal retinal island
(Hamel, 2006). Photopsia is a common but often-neglected symptom
(Heckenlively et al., 1988) that can be highly disturbing to patients.
This phenomenon may be caused by a lack of aﬀerent nerve impulses in
response to photoreceptor degeneration (Kolmel, 1993) or spontaneous
self-signaling activity as a result of inner retina remodeling (Marc et al.,
2003). Photopsia can occur in the early stages of RP (Bittner et al.,
2009), but is most striking—and particularly disturbing—in patients
with more advanced stages of the disease (Bittner et al., 2011). In ad-
vanced RP, the visual hallucinations can take animate forms, which
corresponds with the diagnosis Charles Bonnet syndrome (O'Hare et al.,
2015). Patients with RP can also experience photophobia and dys-
chromatopsia (Hamel, 2006; Pinckers et al., 1993).
2.3. Family history
A thorough family history is very important in any patient suspected
for RP and we recommend drawing a pedigree for each proband. A
pedigree is useful in several ways, it helps assessing the mode of in-
heritance and may also have diagnostic consequences. For example, if
an X-linked inheritance is suspected, the RPGR gene should be se-
quenced prior to whole exome sequencing (see section 6.1). A pedigree
may also illustrate which family members are at risk for developing RP
and/or indicate subjects where non-penetrance should be suspected, for
instance when mutations in PRPF31 and HK1 are involved (see Chapter
4).
2.4. Ophthalmic examination
2.4.1. The classic RP triad
Three clinical features—bone spicule pigmentation, attenuation of
retinal vessels, and a waxy pallor of the optic nerve—are the hallmark
signs of RP. In the early stages of RP, a fundus examination may appear
normal, as bone spicule‒shaped pigment deposits are either absent or
sparse, vascular attenuation is minimal, and the optic disc is normal in
appearance. Prior to the typical RP abnormalities, some patients may
present with aspeciﬁc abnormalities such as irregular reﬂexes from the
internal limiting membrane, broadening of the foveal reﬂex, and dis-
crete local whithish lesions at the level of the RPE. Not all RP patients
develop typical bone spicules; some develop dust-like pigmentation,
whereas others develop nummular hyperpigmentation. The degree of
hyperpigmentation can vary among patients and does not necessarily
reﬂect the severity of the disease. Bone spicule pigmentation consists of
RPE cells that detach from Bruch membrane following photoreceptor
degeneration and migrate to intraretinal perivascular sites, where they
form melanin pigment deposits (Li et al., 1995). These bone spicules
often arise in the mid-periphery, where the concentration of rod cells is
highest (Berson, 1993). Precisely what triggers RPE migration is un-
known, given the high level of interdependence between the chor-
iocapillaris, RPE, and photoreceptors. However, the RPE migration
might be triggered by the reduced distance between the inner retinal
vessels and the RPE, due to the degeneration of photoreceptors in RHO
knock-out mice (Jaissle et al., 2010).
The etiology underlying the attenuation of retinal vessels in RP re-
mains unclear. Initially, this clinical feature was attributed to reduced
metabolic demand following ganglion cell degeneration secondary to
photoreceptor cell loss. An alternative hypothesis attributes the loss of
oxygen-consuming photoreceptors to a hyperoxic state of the remaining
inner retina, which leads to vasoconstriction and reduced blood ﬂow in
retinal vessels (Grunwald et al., 1996; Padnick-Silver et al., 2006; Penn
et al., 2000; Yu and Cringle, 2005). Additionally, Li et al. found that
thickening of the extracellular matrix between the retinal vessels and
the migrated RPE cells causes narrowing of the vessels (Li et al., 1995).
Finally, Stone et al. suggested that a loss of synaptic input secondary to
photoreceptor cell death—and the resulting decline in trophic fac-
tors—causes reduced metabolism of the inner retinal layers, which may
induce vascular remodeling and subsequent vessel attenuation (Stone
et al., 1992). On the other hand, Cellini et al. found that ocular blood
ﬂow was reduced more than would be expected due to retinal atrophy,
which raises the question of whether vascular changes in RP patients
are merely secondary to neuroretinal remodeling, or whether they play
a more pivotal role in the development of RP (Cellini et al., 2010). In
addition, a role for the vasoconstrictor endothelin-1 has been suggested,
although both increased and decreased plasma levels of endothelin-1
have been reported among RP patients, thus indicating the need for
further study (Cellini et al., 2010; Ohguro et al., 2010; Sorrentino et al.,
2015; Strobbe et al., 2015). Given that most of the genes linked to RP
play a role in either the photoreceptor-RPE complex or the inter-
photoreceptor matrix, a secondary cause of these vascular changes is
likely.
The optic disc typically develops a waxy pallor as the disease pro-
gresses; this feature is likely caused by the formation of glial cells both
on the surface and inside the optic disc, resulting in increased light
reﬂectance (Hwang et al., 2012; Szamier, 1981).
2.4.2. Ocular ﬁndings associated with RP
Several other ocular conditions—some of which are amenable to
treatment—are often associated with RP. For example, patients with
early-onset RP can also present with nystagmus, and disease-associated
refractive error is also common. Macular complications can include
cystoid macular edema (CME), macular hole, and epiretinal membrane
formation. CME has been reported to occur in up to 50% of patients
with RP (Strong et al., 2017). Although the etiology remains unknown,
Strong et al. recently proposed several mechanisms that may contribute
to the formation of CME, including i) breakdown of the blood-retina
barrier, ii) impaired function of the RPE pumping mechanism, iii)
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Müller cell edema and dysfunction, iv) anti-retinal antibodies, and v)
vitreomacular traction (Strong et al., 2017). Up to 36% of RP patients
present with epiretinal membrane formation (Chebil et al., 2016;
Fujiwara et al., 2016; Hagiwara et al., 2011; Testa et al., 2014; Triolo
et al., 2013), which may be the result of idiopathic preretinal glial cell
proliferation (Szamier, 1981) or—as suggested recently—may occur
secondary to an inﬂammatory process (Fujiwara et al., 2016). The no-
tion of an inﬂammatory component in RP is not new, as evidenced by
the word “retinitis” in the name, and is generally believed to be sec-
ondary to photoreceptor cell death. Recent evidence, however, suggests
that inﬂammatory cells contribute to retinal degeneration via their
cytotoxic eﬀect on bystander cells such as photoreceptors (Peng et al.,
2014; Zhao et al., 2015). Posterior subcapsular cataract may sig-
niﬁcantly aﬀect vision and occurs in approximately 45% of RP patients
(Auﬀarth et al., 1997; Heckenlively, 1982; Pruett, 1983); visually sig-
niﬁcant cataract can be removed even when there is macular involve-
ment. The underlying mechanism in posterior subcapsular cataract is
currently unknown, although a possible association with inﬂammation
was recently suggested (Fujiwara et al., 2017). Another vitreous ab-
normality that can occur in RP is the presence of vitreous cysts, which
have been reported to occur in 6% of RP patients (Yoshida et al.,
2015b). In addition, optic nerve head drusen and/or optic nerve ﬁber
layer drusen were reported in 9% of a cohort of 262 RP patients (Grover
et al., 1997), and later studies were able to link these drusen to speciﬁc
subtypes of RP (see section 4.9). Finally, RP appears to be one of the
most commonly underlying diseases in patients with secondary retinal
vasoproliferative tumors (Shields et al., 2013).
2.5. Retinal function
2.5.1. Perimetry
Progressive loss of the visual ﬁeld is a characteristic feature of RP.
This visual ﬁeld loss has high bilateral symmetry (Massof et al., 1979)
and typically begins with isolated scotomas in the mid-peripheral areas,
which gradually coalesce to form a partial or complete ring scotoma. As
the disease progresses, this annular scotoma extends both outward
and—albeit more slowly—inward. In addition to ring scotomas, other
patterns of visual ﬁeld progression have been reported, including con-
centric visual ﬁeld loss without a preceding ring scotoma and visual
ﬁeld loss progressing from the superior to inferior retina in an arcuate
pattern (Grover et al., 1998). Kinetic perimetry is best suitable for as-
sessment of peripheral visual ﬁeld loss; the annual rate of decline for
target V4e of the Goldmann perimeter ranges from 2 to 12% and varies
among gene-speciﬁc subtypes (Berson et al., 2002; Haﬂer et al., 2016;
Holopigian et al., 1996; Sandberg et al., 2007, 2008b; Talib et al.,
2017). Progression of central visual ﬁeld loss is usually determined
using static perimetry. A relatively novel technique to assess the central
visual ﬁeld is fundus-driven perimetry (i.e., microperimetry), which
uses precise eye tracking throughout the examination, and enables di-
rect structure-function correlations by providing an annotated en face
image of the posterior pole.
2.5.2. Color vision
Initially, color vision may be normal; however, dyschroma-
topsia—particularly blue-yellow color vision defects where patients
principally experience diﬃculty distinguishing shades of blue from
green and yellow-green from violet—can occur in advanced stages of
the disease. These so-called type III (blue) acquired color vision defects
are more prevalent then type I (red-green) color vision defects (Pinckers
et al., 1993). Blue cone dysfunction has been attributed to the scarcity
of these short-wavelength cones at the fovea (Kolb, 1995). Due to this
uneven distribution, loss of pericentral retinal function may lead to
tritanopia (blue-yellow color blindness). Loss of visual acuity—together
with the associated degeneration of central photoreceptors—increases
the likelihood of developing a type I color defect (Pokorny et al., 1979).
On the other hand, vision loss due to CME seems to have little eﬀect on
color vision (Pinckers et al., 1993).
2.5.3. Dark adaptometry
An abnormal dark-adapted threshold is a hallmark feature of RP.
Rod threshold is often increased due to decreased rod sensitivity and
prolonged recovery of rod sensitivity (Alexander and Fishman, 1984).
Studies regarding dark adaptation in RP revealed increases in both cone
and rod thresholds, a delay in reaching the asymptotic rod threshold, or
the complete loss of rod photoreceptor function (Mantyjarvi and
Tuppurainen, 1994).
2.5.4. Electroretinography
Full-ﬁeld electrophysiological testing—according to the ISCEV
guidelines (http://www.iscev.org/standards)—helps in the diagnosis
and is essential in the quantitative assessment of the severity of the
disease, as well as monitoring disease progression (McCulloch et al.,
2015). Electroretinogram (ERG) abnormalities occur early and precede
the night blindness symptoms and fundus abnormalities (Fig. 2.). On
the dark-adapted, bright ﬂash (combined rod-cone) ERG, the a-wave is
subnormal. In addition, isolated rod responses to a dark-adapted (sco-
topic) dim ﬂash are delayed, diminished, or absent in a full-ﬁeld ERG
recording. Cone responses may also be aﬀected in the early phases of
RP, but this typically lags behind the onset of rod dysfunction. When
present, cone dysfunction manifests in the light-adapted (photopic)
ERG as a delayed and reduced response to a bright ﬂash and 30-Hz
ﬂicker stimuli (Berson, 1981). Oscillatory potentials may also be re-
duced in RP patients (Wachtmeister, 1998). The annual rate of decay in
the full-ﬁeld ERG among RP patients ranges from 9 to 11% (Berson
et al., 1993). The decay in central cone functional is slower (Berson
et al., 1985; Nagy et al., 2008); in a heterogeneous patient cohort in-
cluding all three inheritance patterns (autosomal dominant, autosomal
recessive, and X-linked) and syndromic subtypes, the annual rate of
decay in central cone function was estimated at 4–7% (Falsini et al.,
2012). As the disease progresses, the full-ﬁeld ERG may become non-
recordable despite a residual visual ﬁeld. Under these circumstances,
full-ﬁeld stimulus threshold (FST), a fast test that does not require pa-
tients' ﬁxation, or a multifocal ERG (mfERG) may still be able to elicit
responses and may therefore be used to follow the disease progression
(Messias et al., 2013; Nagy et al., 2008). Delayed responses in the
mfERG may be used to predict visual ﬁeld loss in a healthy-appearing
retina (Hood, 2000).
2.6. Retinal imaging
2.6.1. Fundus imaging
In a single capture, conventional fundus photography covers a ﬁeld
of view of 30–50 degrees of the retina. The peripheral retinal is gen-
erally covered rather poorly, even with 7-ﬁeld fundus photography.
Conventional color fundus photography is limited by media opacities
and inadequate pupillary dilation, and patient cooperation is im-
portant. A better alternative may be found in ultra-wide ﬁeld imaging,
which uses confocal scanning laser ophthalmoscopy (cSLO) with green
and red laser light. Ultra-wide ﬁeld imaging depicts up to 200 degrees
of retina in a single capture (Shoughy et al., 2015; Witmer and Kiss,
2013). This technique, however, also has its disadvantages: the colors
are artiﬁcial, the peripheral image is distorted caused by the two
S.K. Verbakel et al. Progress in Retinal and Eye Research xxx (xxxx) xxx–xxx
4
dimensional image of the three dimensional globe, and structures
anterior to the retina (e.g. eyelashes and vitreous opacities) can cause
artefacts (Witmer and Kiss, 2013). Multicolor imaging is a technique
that uses the reﬂectance of three lasers with a particular wavelength, to
provide information about diﬀerent layers of the retina (Sergott, 2014).
The eventual multicolor image is composed of the reﬂectance images
from the individual lasers, and the coloring is also artiﬁcial. In patients
with RP, multicolor imaging is better at deﬁning the borders of the
intact macular area compared to conventional fundus photography (Liu
et al., 2017).
2.6.2. Optical coherence tomography
The earliest histopathological change in RP is shortening of the
photoreceptor outer segments (Milam et al., 1998). This change is re-
ﬂected in a spectral-domain optical coherence tomography (SD-OCT)
image as disorganization of the outer retinal layers, initially at the in-
terdigitation zone, followed by the ellipsoid zone, and ﬁnally at the
external limiting membrane (Liu et al., 2016) (Fig. 3 and Fig. 4). As RP
progresses, thinning of the outer segments is accompanied by a de-
crease in the thickness of the outer nuclear layer, which contains the
nuclei of the photoreceptor cells. The late stages of RP are characterized
by the complete loss of both the outer segment and the outer nuclear
layer (Hood et al., 2011). In contrast, the inner retinal layers—in-
cluding the inner nuclear layer and the ganglion cell layer—remain
relatively well preserved. In fact, a decrease in the thickness of the
photoreceptor outer segments may even be accompanied by thickening
of the inner retinal layers; although the underlying cause of this
thickening is not entirely clear, it may be related to edema formation in
the retinal nerve ﬁber layer and/or neuronal-glial retinal remodeling in
response to thinning of the outer retina (Aleman et al., 2007). In pa-
tients with advanced disease and atrophy of the outer retinal layers, SD-
OCT imaging may reveal outer retinal tubulations (Goldberg et al.,
2013). Hyperreﬂective foci are a common ﬁnding in the inner nuclear
layer, the outer nuclear layer, and/or the subretinal space. These
hyperreﬂective foci may represent migrating RPE cells and seem to be
correlated with the condition of the RPE layer, the condition of the
ellipsoid zone, and—in some cases—fundoscopically visible hy-
perpigmentation. Interestingly, an absence of hyperreﬂective foci in the
outer nuclear layer has been associated with better visual acuity
(Kuroda et al., 2014). Several studies also revealed a correlation be-
tween the visual acuity in RP patients and the condition of the ellipsoid
zone line (Aizawa et al., 2009; Tamaki and Matsuo, 2011; Witkin et al.,
2006). In addition, the width of the ellipsoid zone line is associated
with a decrease in visual ﬁeld sensitivity. Another study found a linear
correlation between a decrease in the visual ﬁeld and thinning of the
outer segments (Liu et al., 2016).
OCT imaging may also be valuable in diagnosing other macular
abnormalities present in up to half of all RP patients (Makiyama et al.,
2014). For example, CME is the most common ﬁnding, followed by
epiretinal membrane formation, vitreomacular traction syndrome, and
macular hole (Liu et al., 2016). In RP patients with CME, cystoid spaces
are found primarily in the inner nuclear layer, but they can also occur in
the outer nuclear layer, the outer plexiform layer, and/or the ganglion
cell layer (Makiyama et al., 2014).
2.6.3. Fundus autoﬂuorescence imaging
Fundus autoﬂuorescence (FAF) can reveal an otherwise un-
detectable disruption in RPE metabolism. With short-wavelength (SW)-
FAF, using blue or green light, the signal emanates principally from
lipofuscin molecules present in the RPE (Delori et al., 1995). In con-
trast, near-infrared (NIR)-FAF displays the autoﬂuorescence signal that
originates from RPE and—to a lesser extent—choroidal melanin or re-
lated ﬂuorophores (Keilhauer and Delori, 2006). FAF is increasingly
used in evaluating and monitoring the progression of RP; however,
suﬃcient data is lacking regarding the increased susceptibility to light
toxicity of retinas with retinal dystrophies characterized by the accu-
mulation of photosensitizers such as lipofuscin (Hunter et al., 2012;
Teussink et al., 2017).
Dark-adapted 0.01 ERG Dark-adapted 3.0 ERG Light-adapted 3.0 ERG Light-adapted 30-Hz flicker ERG 
Normal
Early RP
Intermediate RP
Advanced RP
(rod-driven response) (rod and cone-driven response) (cone-driven response) (cone-driven response)
Fig. 2. Schematic representation of ERG recordings in diﬀerent stages of RP (i.e. early, intermediate and advanced RP). Vertical lines indicate the moment of stimulus
ﬂash. As the RP progresses, the amplitude of responses decreases, and the implicit time may increase. Cone dysfunction typically lags behind the onset of rod
dysfunction. Eventually, the ERG—under both scotopic and photopic conditions—is extinguished.
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An abnormal foveal ring or curvilinear arc of increased auto-
ﬂuorescence (Fig. 3), not visible on ophthalmoscopy, is present in
50–60% of RP patients (Lois and Forrester, 2015). This ring can be
visualized using both SW-FAF and NIR-FAF. The diameter of the ring
ranges from 3 to 20° and usually has a relatively high level of intero-
cular symmetry (Sujirakul et al., 2015). This hyperautoﬂuorescent ring
represents a transition zone between abnormal and normal retinal
function; thus, function is relatively normal within the ring and absent
outside of the ring. The level of autoﬂuorescence immediately outside
of the ring is relatively preserved, despite severely impaired retinal
function. Moreover, the degeneration of photoreceptor cells outside of
the ring is reﬂected in a loss of the ellipsoid zone and the external
limiting membrane, as well as a thinning or absence of the outer nu-
clear layer in an SD-OCT scan (Lima et al., 2009). The autoﬂuorescent
ring itself corresponds to an area of outer segment dysgenesis and li-
pofuscin production, with progressive retinal thinning, usually accom-
panied by loss of the ellipsoid zone at—or close to—the internal edge of
the ring (Greenstein et al., 2012; Lenassi et al., 2012; Lima et al., 2009;
Murakami et al., 2008). In the majority of patients, the auto-
ﬂuorescence measured inside the ring is quantitatively similar to au-
toﬂuorescence in a healthy eye (Schuerch et al., 2017). Over time, the
diameter of the hyperautoﬂuorescent ring grows smaller; although the
rate of this reduction in diameter varies, relatively large rings tend to
reduce in size more rapidly than small rings. The inner edge of the
constricting ring generally matches the progression of cone system
dysfunction; in contrast, the loss of rod sensitivity is more widespread
and includes the parafoveal area within the ring (Robson et al., 2012).
Eventually, the ring may disperse, and this phenomenon is correlated
with a widespread loss of sensitivity and visual acuity (Robson et al.,
2011, 2012; Wakabayashi et al., 2010). Microperimetry in RP patients
shows that visual sensitivity is relatively preserved within the ring,
reduced in the ring zone itself, and decreased or non-recordable in the
region outside of the ring (Duncker et al., 2013).
Besides the hyperﬂuorescent ring, other autoﬂuorescence patterns
can be observed (see Fig. 5, and section 4.9). In nearly all adult patients
with RP, wide-ﬁeld FAF imaging shows patchy and/or reduced auto-
ﬂuorescence in the mid-periphery, which appears to be related to a loss
of peripheral vision (Oishi et al., 2013). In addition, an abnormal pat-
tern of increased autoﬂuorescence maybe observed at the central ma-
cula and is associated with central visual impairment (Robson et al.,
2011; von Ruckmann et al., 1999; Wakabayashi et al., 2010).
2.6.4. Fluorescein angiography
These days, ﬂuorescein angiography is not commonly used in RP.
On the angiogram, chorioretinal atrophy can be readily observed, in-
itially in the periphery and/or mid-periphery, and later at the posterior
pole. Although there is usually no delay in the ﬁlling of the retinal
vessels, the vessels themselves are attenuated, and some leakage of dye
may be present. The presence and extent of CME is also easily depicted
with ﬂuorescein angiography. Choroidal neovascularization—although
not common in RP—can be visualized with ﬂuorescein angiography
and, more recently, with optical coherence tomography angiography
(OCTA), a non-invasive alternative (Kashani et al., 2017; Sayadi et al.,
2017).
Fig. 3. Horizontal spectral-domain optical coherence tomography (SD-OCT; top
panel) and fundus autoﬂuorescence (FAF) images of the left eye of a patient
with RP. The OCT image shows the perifoveal loss of the outer retinal layers.
The central preservation of the ellipsoid zone corresponds to the internal edges
of the hyperautoﬂuorescent ring visible on FAF.
Fig. 4. Horizontal spectral-domain optical coherence tomography (SD-OCT) images of three patients with RP. (A) SD-OCT image of a 27-year-old female with PDE6B-
associated RP, showing cystoid macular edema and central loss of the ellipsoid zone band (B) SD-OCT image of a 46-year-old male with CDHR1-associated RP,
showing profound loss of photoreceptor outer segments, with central loss of the RPE and increased visibility of the choroidal vasculature. (C) SD-OCT image of a 9-
year-old female with CRB1-associated RP, showing minimal intraretinal cysts, irregular foveal architecture and an increased retinal thickness—despite a generalized
loss of the outer retinal layers—with loss of the retinal laminations.
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2.6.5. Adaptive optics scanning laser ophthalmoscopy
Adaptive optics scanning laser ophthalmoscopy (AOSLO) is a rela-
tively new, non-invasive imaging modality that enables the visualiza-
tion of photoreceptors at a microscopic level by correcting for ocular
aberrations (Georgiou et al., 2017). In patients with RP, the high re-
solution of AOSLO allows early detection of photoreceptor damage,
even when the outer retinal architecture on OCT appears intact (Sun
et al., 2016). In addition, it can reveal a decrease in cone density before
the visual acuity is reduced, since a signiﬁcant cone reduction is pos-
sible before the visual acuity becomes aﬀected (Ratnam et al., 2013).
AOSLO is a highly sensitive imaging modality that may be of additional
value in monitoring disease progression, and evaluating treatment
safety and eﬃcacy in clinical trials.
3. Diﬀerential diagnosis for non-syndromic retinitis pigmentosa
The spectrum of IRDs is broad and includes disorders that primarily
aﬀect the macula (e.g., Stargardt disease and Best vitelliform macular
dystrophy) and stationary disorders such as achromatopsia and CSNB.
Precisely where RP lies within this spectrum is based on both relatively
objective criteria such as symptoms, fundus abnormalities, and ERG
ﬁndings, as well as seemingly arbitrary criteria such as the patient's age
Fig. 5. Fifty-ﬁve-degree fundus auto-
ﬂuorescence (FAF) images of two RP pa-
tients that illustrate the diversity of auto-
ﬂuorescence patterns in RP. (A) FAF image
of 27-year-old female with FAM161A-asso-
ciated RP, showing a curvilinear arc of
hyperautoﬂuorescence surrounding the
macula, in combination with sectoral per-
ipheral hypoautoﬂuorescence in the inferior
quadrants. (B) FAF image of a 55-year-old
female with EYS-associated RP, showing a
well demarcated hyperautoﬂuorescent area
along the inferior vascular arcade, partially
surrounding the fovea.
Table 1
Diﬀerential diagnoses for non-syndromic retinitis pigmentosa.
Inherited retinal dystrophies Syndromic forms of retinitis pigmentosa Pseudoretinitis pigmentosa
Progressive retinal disease
- Cone-rod dystrophy
- Cone dystrophy
- Leber congenital amaurosis
- Bietti crystalline corneoretinal dystrophy
- Late-onset retinal degeneration
- Macular dystrophy (Stargardt disease, Sorsby
fundus dystrophy)
Stationary retinal disease
- Congenital stationary night blindness (including
fundus albipunctatus and Oguchi disease)
Inherited vitreoretinopathies
- X-linked juvenile retinoschisis
- Enhanced S-cone syndrome/Goldmann-Favre
syndrome
- Wagner syndrome/erosive vitreoretinopathy
- Snowﬂake vitreoretinopathy
Chorioretinal dystrophies
- Choroideremia
- Gyrate atrophy
- Helicoid peripapillary chorioretinal
degeneration (Sveinsson chorioretinal atrophy)
- Progressive bifocal chorioretinal atrophy
Female carriers of inherited retinal dystrophies
- Retinitis pigmentosa
- Choroideremia
- Ocular albinism
Ciliopathies
- Usher syndrome
- Bardet-Biedl syndrome
- Cohen syndrome
- Joubert syndrome
- Senior-Løken syndrome
- Sensenbrenner syndrome (cranioectodermal dysplasia)
- Short-rib thoracic dysplasia with or without
polydactyly (includes Jeune, Mainzer-Saldino, Ellis-van Creveld,
and short-rib polydactyly syndrome)
Metabolic disorders
- Alfa-tocopherol transfer protein deﬁciency
(familial isolated vitamin E deﬁciency)
- Bassen-Kornzweig syndrome (abetalipoproteinemia)
- Mucopolysaccharidoses
- Neuronal ceroid-lipofuscinoses, childhood onset (Batten disease)
- Refsum disease (phytanic acid oxidase deﬁciency)
- Mevalonate kinase deﬁciency
- HARP syndrome (hypoprebetalipoproteinemia, acanthocytosis, RP
and pallidal degeneration)
- PHARC syndrome (polyneuropathy, hearing loss, ataxia, RP, and
cataract)
Mitochondrial disorders
- Kearns-Sayre syndrome
- NARP syndrome (neuropathy, ataxia, and RP)
Drug-induced
- Thioridazine and chlorpromazine
- Quinolines (e.g. (Hydroxy)chloroquine)
Chorioretinal infections
- Syphilis, Lyme disease, acute retinal necrosis and
other viral infections (rubella, chicken pox, measles,
cytomegalovirus)
Sequela of inﬂammatory disease
- Sarcoidosis
- Acute posterior multifocal placoid pigment
epitheliopathy
- Birdshot chorioretinopathy
- Serpiginous choroidopathy
- Diﬀuse unilateral subacute neuroretinitis
- Systemic lupus erythematosus
Miscellaneous
- Vitamin A deﬁciency
- Paraneoplastic
- Trauma
- Siderosis bulbi
- Old retinal detachment
- Pigmented paravenous retinochoroidal atrophy
- Acute zonal occult outer retinopathy
A more extensive overview of the diﬀerential diagnoses of non-syndromic retinitis pigmentosa, including clinical features and references, is provided in
Supplementary Table S1.
S.K. Verbakel et al. Progress in Retinal and Eye Research xxx (xxxx) xxx–xxx
7
at onset and even historical factors. Finally, when classifying an IRD, it
is important to take the entire disease course into consideration, as
some phenotypes tend to overlap in late stages. An overview of the
considerations for diﬀerential diagnoses in RP is given in Table 1 (See
Supplementary Table S1 for a more comprehensive overview, including
clinical features).
3.1. Other inherited retinal dystrophies
Early-onset RP has both clinical and genetic overlap with LCA, and
both disorders represent a continuum of retinal dystrophies divided by
indistinct criteria based on the age of onset. Most often, patients who
present at birth or within the ﬁrst few months of life are classiﬁed as
having LCA (Kumaran et al., 2017). The lower age limit for diagnosing
RP has been set by some after infancy (variably deﬁned as age one or
two), resulting in a gray area where both disorders overlap (Kumaran
et al., 2017). In LCA, the extremely early loss of visual function leads to
a set of symptoms that include nystagmus, sluggish or near-absent pu-
pillary response, photophobia, and oculo-digital signs such as poking,
pressing, and rubbing the eyes. Visual acuity is rarely better than 20/
400, and the aspect of the fundus can range from normal to an extensive
atrophic RP-like pigmentary retinopathy. Scotopic and photopic ERG
recordings are generally non-recordable or—at the very least—severely
reduced. Early-onset RP can present with many of these symptoms, and
this overlap with LCA is clearly reﬂected in the number of genes as-
sociated with both disorders (see Fig. 1).
Cone-rod dystrophy is another IRD that has both clinical and genetic
overlap with RP. An ERG recording is not always conclusive with re-
spect to determining which photoreceptors are primarily aﬀected,
particularly in the later stages of the disease. However, the early
symptoms of cone-rod dystrophy, which include early loss of visual
acuity, intense photophobia, variable achromatopsia, and the initial
absence of night blindness, can help the practitioner diﬀerentiate be-
tween cone-rod dystrophy and RP (Hamel, 2007).
Certain retinal dystrophies demonstrate degeneration in a rod-cone
pattern; however, based on their highly speciﬁc phenotype, they have
historically been diﬀerentiated from RP. Examples are choroideremia
(patchy chorioretinal atrophy and normal appearing retinal vessels),
gyrate atrophy (well demarcated circular chorioretinal atrophy with
elevated ornithine levels), and late-onset retinal degeneration (peri-
macular drusen-like lesions and long anterior lens zonules) (Borooah
et al., 2009; Mauthner, 1872). Retinitis punctata albescens also has a
very speciﬁc phenotype; nevertheless, this entity has been considered
an RP subtype throughout most of the literature.
CSNB is an example of a stationary disorder characterized pre-
dominantly by rod dysfunction. With the exception of two subtypes of
CSNB—namely, Oguchi disease and fundus albipunctatus—CSNB pa-
tients generally have a normal fundus. However, CSNB has considerable
overlap with RP with respect to the genes involved; thus mutations in
the PDE6B, RDH5, RHO, RLBP1, and SAG genes can lead to either RP or
CSNB (Zeitz et al., 2015).
3.2. Syndromic RP
Mutations in genes involved in ciliary function often—but not al-
ways—result in a syndromic form of RP. Arguably, the most common
ciliopathy is Usher syndrome, which presents with a variable degree of
neurosensory hearing loss (Boughman et al., 1983). Another well re-
cognized syndromic form of RP is Bardet-Biedl syndrome; in addition to
retinopathy, patients with this syndrome can also present with obesity,
postaxial polydactyly, hypogonadism, renal dysfunction, and/or cog-
nitive impairment (Mockel et al., 2011). The type and extent of these
extra-ocular features in Bardet-Biedl can vary widely and depend—for
the most part—on the speciﬁc gene involved and the speciﬁc mutation
within that gene. Syndromic RP is also associated with systemic me-
tabolic and mitochondrial disorders. The extra-ocular features in syn-
dromic RP can be extremely subtle (for example, an impaired sense of
smell) and/or easily overlooked by the examining ophthalmologist (for
example, in the case of cardiovascular and/or renal disease); on the
other hand, some features can be surgically corrected at an early age
(e.g., polydactyly). Therefore, obtaining a careful, thorough history that
includes these various extra-ocular abnormalities is extremely im-
portant for obtaining a diagnosis. However, genetic analysis may reveal
mutations in a gene that is associated with syndromic forms of RP,
when the initial clinical assessment did not indicate extra-ocular ab-
normalities. In such cases, it is important to reexamine the patient for
the presence of systemic manifestations. For example, patients with
TRNT1-associated RP all demonstrate a mild erythrocytic microcytosis
that is only discovered after analysis of the blood count parameters
(DeLuca et al., 2016). Keep in mind, however, that not all extra-ocular
abnormalities indicate syndromic disease; these abnormalities should
match with the gene involved. A number of genes associated with non-
syndromic RP (e.g. BBS1, CLRN1 and USH2A) may also cause syn-
dromic RP (see Table 2). Correctly diagnosing a patient with syndromic
RP can have sight-saving—or even life-saving—implications, particu-
larly in patients with a metabolic disorder such as Refsum disease or
Kearns-Sayre syndrome, a mitochondrial disorder that often includes
cardiac dysfunction.
3.3. Pseudoretinitis pigmentosa
Several conditions can mimic the clinical features of RP (pheno-
copy) and are classiﬁed as pseudoretinitis pigmentosa (Table 1, Fig.
S1). It is important to distinguish these entities from RP, as several
forms of pseudoretinitis pigmentosa are treatable and do not have an
underlying genetic component. A thorough history, including current
and past medications, lack of interocular symmetry, and lack of disease
progression, may indicate a diagnosis other than RP. Indeed, many
patients who were diagnosed with “unilateral RP” fall in this category,
although a germline mutation in the RP1 gene was reported in a patient
with strictly unilateral RP (Mukhopadhyay et al., 2011).
4. Clinical ﬁndings in genetic subtypes of RP
In Chapter 2, we discussed the typical features attributed to RP in
general. However, the heterogeneous presentation of these conditions
warrants a closer look at the clinical ﬁndings that have been reported
for genetic subtypes of RP. Many early studies used non-genotyped RP
cohorts and occasionally subdivided the patients according to their
inheritance pattern. More recently, however, the phenotype for a spe-
ciﬁc causative gene is described, albeit with limited numbers of patients
and/or a lack of clinical details. Obtaining a clear picture regarding the
phenotypes associated with genetic subtypes of RP is therefore chal-
lenging. In Tables 2 and 3 and Fig. 6, we provide a comprehensive
overview of the speciﬁc clinical features attributed to various subtypes
in order to help the clinician identify the subtype and predict the
clinical course. In addition, a unique atlas containing color fundus
photographs of most RP subtypes is available in Supplementary Fig. S2.
Nevertheless, it is important to realize that even within a speciﬁc
subtype, considerable phenotypic variation can occur due to the vari-
able eﬀects of mutations, genetic modiﬁers, and—in some case-
s—environmental factors.
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4.1. Nomenclature
To understand the relatively confusing nomenclature used for RP
subtypes, one must consider its origins. In the early days of genetic
research on RP, subtypes were numbered according to the order in
which the RP-linked loci were discovered; thus, the RP1 locus at
chromosome 1 was the ﬁrst RP locus discovered. Unfortunately, the
order in which various RP-associated genes were identiﬁed diﬀers from
this locus-based numbering system. For example, the rhodopsin (RHO)
gene was the ﬁrst RP-linked gene identiﬁed; however, the RP subtype
caused by mutations in the RHO gene is actually called RP4, as the RHO
locus was the fourth RP locus identiﬁed. Over the years, the list of RP
subtypes has undergone numerous changes; for example, the RP1 locus
was re-deﬁned from chromosome 1 to chromosome 4, and subtypes
RP5, RP8, RP15, RP16, RP21, and RP52 have been withdrawn. The RP
subtypes are listed in Table 2 and are organized according to the un-
derlying gene (or locus if the causative gene has not been identiﬁed),
rather than the traditional classiﬁcation for RP subtypes, as a classiﬁ-
cation system based on the underlying gene is more informative, less
subject to change, and provides a direct link to the underlying me-
chanism as well as possible therapeutic options.
4.2. Age of onset
In most RP cases, the disease manifests in adolescence; however, the
age of onset for RP varies widely. Table 3 summarizes the genes asso-
ciated with early-onset and late-onset RP. Early forms of RP and LCA
have many causative genes in common; these common genes—with the
exceptions of the CWC27, IMPDH1, and CRX genes—are all associated
with an onset of RP before the age of ﬁve years. HGSNAT-linked RP can
manifest either early or later in life, ranging from well under the age of
10 years to after the ﬁfth decade; this wide range in onset is likely due
to a large genetic-modifying eﬀect. In addition to HGSNAT, two other
RP genes—CRX and RBP3—have also been associated with late-onset
RP. In patients who develop symptoms at a later age, one must always
consider the possibility of a pseudoretinitis (see Table 1).
4.3. Refractive errors
Both myopia and hyperopia—particularly high myopia (odds ratio
10.1) and high hyperopia (odds ratio 9.7) —are more prevalent in RP
patients compared to the general population (Hendriks et al., 2017).
Hyperopia is typical among RP patients with mutations in the CRB1
(Talib et al., 2017), LRAT (den Hollander et al., 2007), or the NR2E3
(Bandah et al., 2009) gene. Interestingly, hyperopia is frequently as-
sociated with LCA, particularly among patients with a mutation in the
GUCY2D, RPGRIP1, CRX, or CEP290 gene (Hanein et al., 2006). Myopia
is associated with Usher syndrome and the following ﬁve genetic
subtypes of RP: RP1, RBP3, and ZNF408 in autosomal recessive RP, and
RPGR and RP2 in X-linked RP (Arno et al., 2015; Avila-Fernandez et al.,
2015; Chassine et al., 2015; Habibi et al., 2017; Hendriks et al., 2017;
Krantz et al., 2010).
4.4. Pigmentary abnormalities
4.4.1. Peripheral retinal pigmentation
In addition to the typical bone spicule pigmentation that originates
in the mid-periphery of the retina and has an apparent predilection for
the perivascular area, other shapes and/or localizations have also been
reported. Round clumps of pigment are common in patients carrying
mutations in the ARHGEF18 (Arno et al., 2017), GNAT1 (Carrigan et al.,
2016), NR2E3 (Bandah et al., 2009), or NRL (Bessant et al., 2003) gene.
In BEST1-associated RP, these pigments are typically located in the
outermost periphery of the retina (Davidson et al., 2009). Para-arter-
iolar absence of pigmentation is a feature of RP in patients with mu-
tations in the CRB1 (Talib et al., 2017; van den Born et al., 1994),
PRPF31 (Fig. S2) or RDH12 (Mackay et al., 2011) gene.
4.4.2. Absence of retinal hyperpigmentation
An absence or scarcity of typical RP-related hyperpigmenta-
tion—known as RP sine pigmento—has been described in several RP
subtypes (see Table 3), although this ﬁnding may also be related to the
fact that pigmentation is sometimes absent in the early stages of RP
(Pearlman et al., 1976). The absence of pigmentation in RP patients
over 20 years of age has been reported in patients with mutations in the
RLBP1 (Bocquet et al., 2013; Hipp et al., 2015), RP1 (Ma et al., 2013),
RPGRIP1 (Booij et al., 2005; Huang et al., 2017a), and USH2A (Chen
et al., 2014) genes; it is important to note, however, that only the pa-
tient with RP1-associated RP was over 30 years of age. The reason for
this lack of retinal hyperpigmentation is unclear, although myopic de-
generation may be a factor in some RP patients (Bandah-Rozenfeld
et al., 2010b). Nevertheless, an absence of pigmentation should not be
used to exclude a diagnosis of RP, particularly in young patients, al-
though other disorders (Table 1) should also be considered. Minimal
pigmentary changes have also been associated with mutations in the
BBS genes; however, with the exception of TTC8 (BBS8), this only
concerns syndromic cases (Deveault et al., 2011; Priya et al., 2016).
4.4.3. Pigmentary abnormalities in the macula
In certain RP subtypes, central RPE alterations and atrophy occur
relatively early in the disease course (i.e., earlier than one would expect
based on the degree of visual ﬁeld constriction). These subtypes are
associated with a more rapid decline in visual acuity (Flynn et al.,
2001) and can be diﬃcult to distinguish from a cone-rod dystrophy.
The genes associated with early macular atrophy are listed in Table 3.
In patients with the DHX38 (Ajmal et al., 2014) or IDH3A (Pierrache
Table 3
Common clinical characteristics of the genetic subtypes of non-syndromic RP.
Clinical feature Associated genes
Age of onset< 5 years BBS1, C2orf71, C8orf37, CRB1, CNGA1, DHX38, FSCN2, IDH3A, IFT140, LRAT, MERTK, NR2E3, NRL, OFD1, PDE6G, PRPF3,
PRPF31, RBP3, RDH12, RP2, RP32 locus, RPE65, RPGR, RPGRIP1, SNRNP200, SPATA7, TTC8, TULP1
Age of onset< 10 years ABCA4, AGBL5, BBS2, BEST1, CLN3, CNGB1, CWC27, HGSNAT, IFT172, IMPDH1, IMGP2, PDE6A, PDE6B, POMGNT1, PRCD,
PROM1, PRPF8, REEP6, RHO, RLBP1, RP9, SLC7A14, ZNF513, RP6 locus, RP22 locus, RP24 locus
Age of onset> 50 years CRX, RBP3, HGSNAT
Early macular atrophy C2orf71, C8orf37, CDHR1, CERKL, CRX, DHX38, FSCN2, GUCA1B, HK1, IDH3A, IFT140, IMPG2, MERTK, PROM1, PRPF6,
RDH12, RP2, RPGR, RPGRIP1, SAG, SPATA7, TTC8, ZNF513
Bull's eye maculopathy BBS2, CDHR1, CRB1, IMPG2, HK1, MERTK, NRL, PRCD, PROM1, RP2, RP32 locus
Dense pigment migration BEST1, CDHR1, CRB1, EYS, IFTA140, PDE6A, PDE6B, PRPF8, RDH12, SNRNP200
Absence/scarcity of retinal hyperpigmentation CDHR1, CLN3, FAM161A, HGSNAT, LRAT, NRL, OFD1, RLBP1, RP1, RPE65, RPGRIP1, TTC8, USH2A
Pericentral pigmentary retinopathy CERKL, CNGA1a, CNGB1a, CRXa, DHDDSa, HGSNAT, HK1, NR2E3, PDE6B, PRPF31a, PROM1a, PRPH2, RHO, TOPORS, TULP1a, USH2A
For references, see Supplementary Table 2.
a Phenotype described once.
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Fig. 6. Fundus photographs of patients with various non-syndromic RP subtypes. (A) Composite fundus photograph of a 47-year-old male patient with USH2A-
associated RP, showing bone spicule pigmentation in the mid-periphery, and attenuated vessels. (B) Composite fundus photograph of a 59-year-old female patient
with IMPG2-associated RP, showing marked bone spicule pigmentation in the mid-periphery, waxy pallor of the optic disc, attenuated vessels, and macular atrophy.
(C) Composite fundus photograph of a 27-year-old female patient with PDE6B-associated RP, showing bone spicule pigmentation in the mid-periphery, vessel
attenuation, and CME. (D) Composite fundus photograph of a 46-year-old male patient with CDHR1-associated RP, showing vessel attenuation, bone spicule like
pigmentation, and patchy atrophy in the periphery and macula. (E) Composite fundus photograph of a 67-year-old male patient with CNGB1-assocated RP, showing
attenuated vessels, RPE atrophy, and mid-peripheral pigment clumping. (F) Composite fundus photograph of a 21-year-old male RP patient carrying a mutation in the
CRB1 gene, showing dense pigment migration with para-arteriolar absence of pigmentation. (G) Fundus photograph of a 42-year-old female patient with CA4-
associated RP, showing the classical triad of bone spicule pigmentation in the mid-periphery, attenuated vessels, and waxy pallor of the optic disc. (H) Fundus
photograph of a 46-year-old female RPGR carrier, showing a tapetal-like fundus reﬂex.
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et al., 2017) subtype, the macular atrophy is often referred to as ma-
cular pseudocoloboma, which is a rather unfortunate term, as a pseu-
docoloboma should not be confused with a “true” coloboma, which
results from a closure defect in the embryonic ﬁssure during develop-
ment and is often accompanied by other closure defects. In contrast to a
loss of pigmentation due to RPE atrophy, deposits of macular pigments
have been described in early-onset RP subtypes due to mutations in
either the ABCA4 or RDH12 (Cremers et al., 1998; Schuster et al., 2007)
gene. In these subtypes, the pigment deposits extend from the per-
iphery/mid-periphery to the macular region; in other subtypes, the
macula usually remains free of pigment clumping.
4.5. Cystoid macular edema
CME is a common ﬁnding among RP patients and is prevalent in all
age groups (Hajali et al., 2008) (Table 2). The reported prevalence
among patients with an autosomal dominant form of RP is relatively
high (Sandberg et al., 2008a; Testa et al., 2014), although this ﬁnding
has not been widely conﬁrmed by other groups (Hajali et al., 2008;
Liew et al., 2015; Makiyama et al., 2014). One report also suggested an
association between CME and female patients (Testa et al., 2014). The
relatively high prevalence of CME among RP patients suggests that it
may not be subtype-speciﬁc. A combination of CME and cells in the
vitreous body has been reported in children with variants in the CRB1
or RP1 gene, as well as in young adults with mutations in the PRPF31
or USH2A gene (Hettinga et al., 2016; Murro et al., 2017). This
combination of clinical ﬁndings can lead to an incorrect diagnosis of
intermediate uveitis, particularly in children with RP in which retinal
abnormalities are subtle or even absent (Verhagen et al., 2016; Yoshida
et al., 2013). The therapeutic opticons for CME are discussed in section
6.3.
4.6. Vascular abnormalities
Coats-like exudative retinopathy, which is characterized by retinal
telangiectasia, lipid deposits, and exudative retinal detachment, has
been reported in 7–15% of patients with CRB1-associated RP (Aleman
et al., 2011; Henderson et al., 2011; Mathijssen et al., 2017; Talib et al.,
2017) and in one patient with a mutation in exon ORF15 in the RPGR
gene (Demirci et al., 2006). Unlike Coats' disease, which is usually
unilateral, the Coats-like phenotype in RP patients is frequently bi-
lateral (Khan et al., 1988). However, not all aﬀected siblings present
with the Coats-like phenotype, which suggests the presence of non-
genetic factors (den Hollander et al., 2001). Finally, vascular sheathing
has been reported in some patients with mutations in the CRB1 gene
(van den Born et al., 1994), IMPG2 (van Huet et al., 2014), or REEP6
gene (Fig. S2).
4.7. Localized forms of RP
4.7.1. Sector RP
Although RP is considered a generalized photoreceptor dystrophy,
Fig. 7. Estimated relative contribution of genes to non-syndromic retinitis pigmentosa. The estimates are based on personal experience and a search of the literature.
It is important to realize that the frequency may vary depending on the geographic region.
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in some patients the retinal abnormalities are limited to a speciﬁc re-
gion of the retina. In 1937, Bietti was the ﬁrst to describe a form of RP
in which the pigmentary alterations were limited to the inferonasal
quadrant of both eyes (Bietti, 1937). This so-called sector RP is an
atypical form of RP characterized by symmetrical areas of regional
pigmentary alterations, usually restricted to the inferior quadrants of
the retina (Van Woerkom and Ferrucci, 2005). Visual ﬁeld defects often
correspond to the boundaries of these retinal pigmentary alterations,
although the abnormalities visible on ﬂuorescein angiography and ERG
can extend beyond the aﬀected areas seen with ophthalmoscopy
(Abraham, 1975; Abraham et al., 1976). Sector RP usually progresses
slowly, but can evolve to a panretinal RP phenotype (Hellner and
Rickers, 1973; Ramon et al., 2014). Sector RP has been described pri-
marily in patients with an autosomal dominant form of RP caused by
pathogenic mutations in the RHO gene (Heckenlively et al., 1991;
Ramon et al., 2014; Sullivan et al., 1993). Other groups have reported
sector RP in GUCA1B-associated autosomal dominant (Sato et al., 2005)
and RPGR-associated X-linked forms of RP (Charng et al., 2016;
Heckenlively, 1988). Nevertheless, why the atrophic pigmentary ab-
normalities are initially limited to a speciﬁc region—despite the fact
that the underlying molecular defects are most likely expressed ubi-
quitously throughout the retina—remains unclear. Localized diﬀer-
ences in the retina's exposure to light have been suggested as a possible
explanation in RP patients with mutations in the RHO gene (Ramon
et al., 2014).
4.7.2. Pericentral pigmentary retinopathy
Several RP genes have been associated with pigmentary alterations
and annular chorioretinal atrophy that extends temporal from the optic
disc along or adjacent to the vascular arcade and tends to spare the far
periphery (Table 3) (Chakarova et al., 2007; Comander et al., 2017;
Matsui et al., 2015; Sullivan et al., 2014). The clinical ﬁndings reported
in this pericentral pigmentary retinopathy (PPR) vary among patients,
including both slow progression and stationary forms of the disease (de
Crecchio et al., 2006; Matsui et al., 2015; Sandberg et al., 2005). PPR
can be considered part of the RP spectrum, particularly in patients with
progressive disease, a history of night blindness, an annular scotoma,
and reduced rod activity measured on ERG. This clinical picture cor-
responds with reports that family members of PPR patients can present
with a more typical RP phenotype (Matsui et al., 2015). PPR can re-
semble pigmented paravenous retinochoroidal atrophy (PPRCA) and
postinﬂammatory changes in retinal pigmentation.
4.8. Retinitis punctata albescens
Some RP patients can present with white punctate deposits that are
distributed diﬀusely throughout the retina and often decrease in
number before the onset of atrophy. Although this clinical phenomenon
has been described as a distinct form of retinal dystrophy called retinitis
punctata albescens, it can also be considered a descriptive subtype of
non-syndromic RP. Retinitis punctata albescens can be caused by mu-
tations in the LRAT (Littink et al., 2012), PRPH2 (Kajiwara et al., 1993),
RHO (Souied et al., 1996), or RLBP1 (Morimura et al., 1999) genes.
Mutations in the RLBP1 gene have also been associated with Bothnia
retinal dystrophy (Burstedt et al., 1999) and Newfoundland rod-cone
dystrophy (Eichers et al., 2002), two speciﬁc RP subtypes characterized
by the same white punctate deposits present in retinitis punctata al-
bescens (Burstedt et al., 2001). These white deposits have been attrib-
uted to the accumulation of all-trans-retinyl esters in the RPE (Saari
et al., 2001); however, given that retinitis punctata albescens patients
with LRAT mutations produce little to no retinyl esters, the precise
composition of these deposits remains unclear (Dessalces et al., 2013).
4.9. Miscellaneous
Optic disc drusen are a common ﬁnding in RP patients, particularly
patients with mutations in the CRB1 gene, in which the prevalence
approaches 1 in 3 patients (Mathijssen et al., 2017; Talib et al., 2017).
A tapetal-like fundus reﬂex is a yellow-golden sheen similar to the
Mizuo-Nakamura phenomenon observed in Oguchi disease, although
this sheen typically does not disappear after dark adaption. This reﬂex
is best visualized using red-free or near-infrared reﬂectance (Acton
et al., 2013). Originally, this ﬁnding was believed to be pathognomonic
for female carriers of RPGR-associated RP; however, it has also been
reported in female carriers of X-linked RP2 (Flaxel et al., 1999).
Besides the well-recognized hyperautoﬂuorescent ring, other FAF
characteristics have been reported in certain genetic subtypes. For ex-
ample, mutations in the RPE65 or LRAT gene, which are both involved
in the visual cycle, can lead to a reduced or even absent signal on FAF
imaging (Dev Borman et al., 2012; Lorenz et al., 2004). The presence of
2 or 3 hyperautoﬂuorescent rings has been associated with mutations in
the NR2E3 gene (Coppieters et al., 2007; Escher et al., 2012).
5. Genes and proteins involved in RP
To date, 84 genes (Fig. 7) and 7 candidate genes have been linked to
non-syndromic RP. Each of these genes encodes a protein that plays a
role in vital processes within the neuroretina and/or RPE (e.g., the
phototransduction cascade and the visual cycle) or an underlying
structure (e.g., the connecting cilium). Therefore, a mutation in a gene
within a speciﬁc pathway can cause the whole pathway to become
impaired or even disrupted entirely. In principle, a certain degree of
clinical overlap is to be expected among RP subtypes that are caused by
mutations in genes associated with a common pathway. In practice,
however, genetic variants that modify a pathway's activity can increase
the clinical and/or genetic heterogeneity of diseases that involve a
common pathway. Identifying the pathways aﬀected in non-syndromic
RP is therefore important for understanding the underlying pathogen-
esis. In this chapter, we provide an overview of the principal pathways
that are aﬀected in RP, and we discuss the location and function of the
genes/proteins involved in RP (Fig. 8, Table S3). Speciﬁcally, we focus
on the phototransduction cascade (with 10 RP genes involved), the
visual cycle (7 RP genes), ciliary structure and transport (35 RP genes),
and the interphotoreceptor matrix (1 RP gene); the remaining 38 RP
genes and their function are listed in Table S3.
5.1. The phototransduction cascade
The phototransduction pathway is a cascade of successive reactions
triggered by excitation of the opsin molecule by a photon, resulting in
an electrical signal that is transmitted via the optic nerve to the visual
cortex, leading to the perception of an image (see panel 3 in Fig. 8).
This cascade is largely similar between rods and cones, with slight
diﬀerences due to their diﬀerent functions in dim light versus bright
light.
In rod cells, rhodopsin (encoded by the RHO gene) consists of the
apoprotein opsin and the chromophore 11-cis-retinal. Upon capturing a
photon, 11-cis-retinal converts to the all-trans-retinal isomer, which
changes the structure of rhodopsin into that of the photoactive me-
tarhodopsin II (Wald, 1968). Metarhodopsin II activates the G protein
transducin (encoded by the GNAT1 gene), which then activates the
cyclic guanosine monophosphate (cGMP) phosphodiesterase (with
subunits encoded by the PDE6A, PDE6B, and PDE6G genes), which
hydrolyzes cGMP to form 5′-GMP (Stryer, 1986). This process decreases
the concentration of cGMP in the photoreceptor's cytoplasm, which
closes cGMP-gated cation channels (with subunits encoded by the
CNGA1 and CNGB1 genes) in the plasma membrane. This in turn hy-
perpolarizes the plasma membrane due to a large decrease in in-
tracellular calcium concentration; this hyperpolarization of the plasma
membrane leads to decreased glutamate release at the photoreceptor's
synapse.
After phototransduction, the system returns to the pre-photoactivation
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state via the following steps: i) phosphorylation of metarhodopsin II by
rhodopsin kinase and the subsequent binding of arrestin (encoded by the
SAG gene), which deactivates transducin (Gurevich et al., 2008; Palczewski,
1994); ii) dissociation of all-trans-retinal from the visual pigment and con-
version to 11-cis-retinal via the visual (retinoid) cycle (see below); iii) in-
activation of transducin by GTPase-accelerating proteins (in particular,
RGS9), thereby inactivating the phosphodiesterase (Krispel et al., 2006;
Pugh, 2006); and iv) the return of intracellular cGMP to normal levels by
guanylate cyclase (encoded by the GUCY2D gene) which is activated by
guanylate cyclase‒activating protein (encoded by the GUCA1A GUCA1B,
and GUCA1C genes) (Haeseleer et al., 1999; Koch and Stryer, 1988). After
all-trans-retinal has dissociated from opsin, 11-cis-retinal binds to opsin to
produce rhodopsin, which then dissociates from arrestin. Rhodopsin is then
de-phosphorylated by protein phosphatase 2A. Thus, in the dark, rhodopsin
is predominantly in the non-phosphorylated state.
The majority of molecules in the rod phototransduction cascade
have a homolog that performs a similar function in cone cells. There are
two principal diﬀerences between rods and cones with respect to pho-
totransduction. First, cone cells express three diﬀerent opsins, each of
which is speciﬁc—albeit less sensitive—to a given wavelength. Second,
opsins in cone cells have faster kinetics than rod opsins and are nearly
unsaturable. Although the functional consequence of this diﬀerence in
kinetics is not completely clear, most research suggests that the faster
kinetics in cones translates to a shorter recovery phase. This may be due
to the more rapid phosphorylation of activated cone pigments, a faster
dissociation rate of all-trans-retinal, and/or faster inactivation kinetics
of transducin (Tachibanaki et al., 2001, 2005). Hydrolysis of trans-
ducin-bound GTP is the rate-limiting reaction in rod cells; however,
compared to rods, cones contain ten-fold higher concentrations of the
GTPase-accelerating protein complex.
5.2. The visual cycle
The vitamin A derivative 11-cis-retinal is an essential component in
the phototransduction cascade. Dietary vitamin A (all-trans-retinol) is
absorbed from the blood, enters the RPE, and is converted to 11-cis-
retinal. The visual cycle is a complex process that focuses on re-
generating 11-cis-retinal from all-trans-retinal produced in the photo-
transduction cascade (see panel 4 in Fig. 8) and occurs simultaneously
with phototransduction.
Upon photoactivation, all-trans-retinal is released from the activated
visual pigment into the lumen of the outer segment discs, where it re-
acts with phosphatidylethanolamine to form N-retinylidene-phospha-
tidylethanolamine (Liu et al., 2000). Via the ﬂippase activity of the ABC
(ATP-binding cassette) transporter ABCR (encoded by the ABCA4 gene),
all-trans-retinal is released into the cytoplasm of the photoreceptor,
where it is reduced to all-trans-retinol by the enzyme all-trans-retinal
dehydrogenase (encoded by the RDH8, RDH12, and RDH14 genes)
(Haeseleer et al., 1998; Rattner et al., 2000). All-trans-retinol is then
transported into the subretinal space, where it binds to inter-
photoreceptor retinoid‒binding protein (IRBP, encoded by the RBP3
gene) and is transported to the RPE (Gonzalez-Fernandez, 2002). In the
cytoplasm of the RPE cell, all-trans-retinol binds to cellular re-
tinol‒binding protein (encoded by the CRBP1 gene) and is re-iso-
merized via a cascade involving lecithin-retinol acyltransferase (LRAT),
RPE65 (also known as retinoid isomerohydrolase), retinal G protein-
coupled receptor (RGR), and 11-cis-retinol dehydrogenase (encoded by
the RDH5 and RDH11 genes) (Deigner et al., 1989; Moiseyev et al.,
2005; Saari and Bredberg, 1989; Saari et al., 2001; Trehan et al., 1990).
The resulting 11-cis-retinal is then transported into the inter-
photoreceptor matrix by cellular retinaldehyde‒binding protein
(CRALBP, encoded by the RLBP1 gene) and is subsequently transported
back into the photoreceptor's cytoplasm by IRBP. Once back in the
photoreceptor, 11-cis-retinal binds to opsin to form a new rhodopsin
molecule. This pathway, known as the canonical visual cycle, catalyzes
the re-isomerization of retinal in rod cells.
Recent studies have shown that in addition to the above-mentioned
visual cycle, cones also have a second, non-canonical visual cycle that
operates in cone outer segments and Müller cells (see panel 5 in Fig. 8);
this cycle regenerates 11-cis-retinal at a 20-fold faster rate (Mata et al.,
2002; Tang et al., 2013), although all of the proteins in this cycle have
not yet been identiﬁed. This cycle is initiated when cone-speciﬁc opsin
is photobleached and releases all-trans-retinal into the cell's cytosol,
where it is then reduced to all-trans-retinol by retinol dehydrogenases
(encoded by the RDH8 and RDH14 genes) and the cone-speciﬁc enzyme
retSDR1 (encoded by the DHRS3 gene) (Sahu and Maeda, 2016). All-
trans-retinol then binds to IRBP and is transported into Müller cells,
where dihydroceramide desaturase-1 (DES1, encoded by the DEGS1
gene) catalyzes the direct isomerization of all-trans-retinol to produce
11-cis-retinol, as well as 9-cis-retinol and 13-cis-retinol (Kaylor et al.,
2013; Tang et al., 2013). Because the isomerization reaction catalyzed
by DES1 is reversible (Kaylor et al., 2013), the newly formed 11-cis-
retinol is susceptible to re-isomerization. The cell uses two mechanisms
to reduce this susceptibility to re-isomerization. First, 11-cis-retinol can
be esteriﬁed by multifunctional O-acyltransferase (MFAT, encoded by
the AWAT2 gene) to form 11-cis-retinyl-ester, and secondly, newly
formed 11-cis-retinol can be captured by CRALBP (Kaylor et al., 2014).
A currently undeﬁned 11-cis-retinol-ester hydrolase (labeled “REH?” in
Fig. 8) hydrolyzes 11-cis-retinyl-ester to form 11-cis-retinol; this occurs
only when CRALBP is available to bind 11-cis-retinol and prevent re-
isomerization by DES1 (Stecher et al., 1999). When bound to CRALBP,
11-cis-retinol is released into the interphotoreceptor matrix, where it
binds IRBP and is taken up by the cone outer segment (Saari et al.,
2009). There, an unknown RDH (labeled “RDH?” in Fig. 8) oxidizes 11-
cis-retinol to form 11-cis-retinal, which then binds to opsin, forming a
new pigment molecule. This ﬁnal oxidation reaction can occur in cone
outer segments, but not in rod outer segments (Tang et al., 2013); thus,
the non-canonical visual cycle is speciﬁc to cone cells.
5.3. Ciliary transport
Cilia are slender, longitudinal, microtubule-based projections that
extend from the surface of most mammalian cells and vary in both
shape and size depending on the cell type (Satir and Christensen, 2008).
Cilia can be divided in two main categories: motile cilia and non-motile
(primary) cilia. Motile cilia are used in speciﬁc organs and processes
that require the movement of ciliary ﬂuid; examples include the es-
tablishment of left-right asymmetry of viscera in the developing em-
bryo, the clearance of mucus from the airways, and sperm motility. In
contrast, primary cilia are present on the vast majority of non-motile
eukaryotic cells and serve as sensory “antennae” in most sensory organs
(Berbari et al., 2009; Singla and Reiter, 2006). Given the nearly ubi-
quitous presence of cilia throughout the body, mutations in genes en-
coding ciliary proteins can lead to so-called ciliopathies, which often
involve a syndromic phenotype with multiple aﬀected organs and cel-
lular processes (Hildebrandt et al., 2011; Reiter and Leroux, 2017).
Photoreceptor cells contain a highly specialized sensory cilium that
consists of the connecting cilium and associated basal body, as well as
Fig. 8. Schematic representation of a human rod photoreceptor (purple), cone photoreceptor (orange), Müller cell (blue), RPE cells (brown), and the inter-
photoreceptor matrix (beige). The six separate panels provide detailed information regarding the genes involved in four key processes (panels 1, 3, 4, and 5) and two
structures (panels 2 and 6). Note that genes are not shown in italics. These processes are described in detail in sections 5.1–5.5.; Abbreviations: cGMP: cyclic
guanosine monophosphate; GCAP: guanylate cyclase-activating protein; GDP: guanosine diphosphate; GTP: guanosine triphosphate; PDE: phosphodiesterase;
RHAMM: receptor for hyaluronic acid-mediated mobility; RHO*: activated rhodopsin; RPE: retinal pigment epithelium.
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an apical outer segment, a highly specialized structure in which pho-
totransduction takes place (Roepman and Wolfrum, 2007). Because the
outer segment lacks biosynthetic machinery, all of its components are
synthesized and partially pre-assembled in the inner segment and then
transported to the outer segment via the connecting cilium, a process
facilitated by intraﬂagellar transport (IFT). IFT is also used to assemble
and maintain the cilia (Bhogaraju et al., 2013a; Hao et al., 2011;
Kozminski et al., 1993; Kubo et al., 2016; Ye et al., 2013). To date,
mutations in more than 30 ciliary protein‒encoding genes have been
linked to non-syndromic retinal diseases (Table S3) (Daiger et al., 2017;
Estrada-Cuzcano et al., 2012b). The functions of these ciliary proteins
in the connecting cilium have been identiﬁed, and most of these pro-
teins are involved in either IFT function/regulation or ciliary structure.
IFT is a bidirectional transport system that uses microtubule-based
motor molecules to transport cargo both from the cilia's base to the tip
(i.e., anterograde transport, which is driven by kinesin motor proteins)
and from the tip to the base (i.e., retrograde transport, which is driven
by dynein motor proteins) (Rosenbaum and Witman, 2002; Scholey,
2003; Wren et al., 2013). This transport system is capable of moving
thousands of molecules per second in each photoreceptor cell, including
the anterograde transport of RHO and the light-dependent transport of
arrestin and transducin (Besharse et al., 1977; Sokolov et al., 2002;
Strissel et al., 2006; Young, 1968).
Many genes associated with non-syndromic RP encode proteins that
are involved in various aspects of ciliary transport (Table S3). For ex-
ample, ARL3 and RP2 mediate the localization of motor units at the
ciliary tip (Schwarz et al., 2017). In addition, IFT is mediated by the so-
called IFT proteins (e.g., IFT140 and IFT172) that form two complexes
(complex A and complex B), which bind and transport ciliary cargo
(Bhogaraju et al., 2013b; Taschner et al., 2012). Moreover, the BBSome
complex (in which BBS stands for Bardet-Biedl syndrome) serves as an
adaptor between cargo and the IFT complex (Mourao et al., 2016;
Nachury et al., 2007). The BBSome complex consists of eight protein
subunits (BBS1, -2, -4, -5, -7, -8 (TTC8), -9, and -18) (Mourao et al.,
2016). Mutations in BBSome subunits generally give rise to Bardet-
Biedl syndrome (Mockel et al., 2011); however, four of the genes that
encode BBSome subunits (BBS1, BBS2, BBS9, and TTC8), as well as the
gene that encodes ARL6 (a protein that recruits the BBSome complex to
the membrane), are associated with non-syndromic RP (Abu-Saﬁeh
et al., 2012; Estrada-Cuzcano et al., 2012a; Goyal et al., 2015; Jin et al.,
2010; Mourao et al., 2014; Murphy et al., 2015; Pretorius et al., 2011;
Riazuddin et al., 2010; Shevach et al., 2015).
The entry and exit of cargo on the ciliary IFT machinery is regulated
by the “ciliary gate”, a specialized ciliary structure located at the base
of the primary cilium; this structure forms a general barrier against
periciliary particle diﬀusion and therefore regulates transport to and
from the structurally isolated outer segment (Christensen et al., 2007;
Emmer et al., 2010; Goncalves and Pelletier, 2017; Leroux, 2007;
Nachury et al., 2010; Rosenbaum and Witman, 2002). The gate's
function is mediated by transition ﬁbers and the transition zone.
Transition ﬁbers (also known as distal appendages) anchor the cilium to
the plasma membrane, and the transition zone is a modular structure
containing Y-shaped linkers that are believed to act as a “molecular
sieve” in order to restrict and select the entry and exit of ciliary cargo.
The photoreceptor-connecting cilium is both structurally and func-
tionally analogous to a prototypical transition zone. However, the
elongated shape of this cilium is likely required to achieve the high
traﬃcking rate for transporting biosynthetic material, as approximately
10% of the outer segment is renewed each day through shedding and
replacement of materials at the tip (Young, 1967). In addition, a ciliary
pore complex, which is homologous to the nuclear pore complex,
functions as an active molecule gate at the base of the cilium (Takao
and Verhey, 2016). Two interacting protein modules—namely, the
Meckel/Joubert syndrome (MKS/JBTS) and nephronophthisis (NPHP)
associated modules—assemble the transition zone and control its gating
function (Chih et al., 2011; Garcia-Gonzalo et al., 2011; Sang et al.,
2011). These modules consist of several ciliopathy-associated proteins
and interact with nearby transition zone components (e.g., the BBSome
complex) and a complex that contains the protein encoded by the RPGR
gene, which accounts for 70–90% of X-linked RP cases and 10–20% of
all RP cases (Goncalves and Pelletier, 2017; Megaw et al., 2015). The
RPGR protein is anchored to the connecting cilium by RPGR interacting
protein 1 (RPGRIP1), the localization of which requires another ciliary
protein, spermatogenesis-associated protein 7 (SPATA7). Defects in the
RPGR-RPGRIP1-SPATA7 complex lead to the aberrant localization of
speciﬁc opsins; therefore, this complex is believed to play a role in the
transport of speciﬁc opsins (Eblimit et al., 2015). For a thorough
overview of the interactions between RPGR and other ciliary proteins
such as centrosomal protein 290 (CEP290), phosphodiesterase 6D
(PDE6D), nephrocystin 1 (NPHP1), nephrocystin 4 (NPHP4), and
Whirlin (WHRN), the reader is referred to a recent review by Megaw
and colleagues (Megaw et al., 2015).
5.4. Outer segment structure
The cilium of the photoreceptor cell consists of the connecting ci-
lium and the outer segment, the latter of which contains a highly spe-
cialized compartment consisting of stacks of intracellular discs (in rod
cells) or lamellae (in cone cells) (Cohen, 1961; Sjostrand, 1953).
Goldberg et al. reviewed the morphogenesis and architecture of in-
tracellular discs in the outer segment (Goldberg et al., 2016). Some
subtypes of non-syndromic RP are associated with proteins that are
involved in the development and/or orientation of outer segment discs
(Table S3 and Fig. 8), and their genes are discussed below.
Outer segment discs develop from the connecting cilium as evagi-
nations in the plasma membrane that are subsequently internalized to
form a stack of intracellular discs (Ding et al., 2015). F-actin micro-
ﬁlaments located at basal axonemal microtubules are required for the
initiation of new disc evagination (Goldberg et al., 2016). The RP-as-
sociated gene FSCN2 encodes retinal fascin homolog 2 (FSCN2), which
crosslinks and bundles F-actin ﬁlaments (Saishin et al., 2000; Tubb
et al., 2000). Peripherin-2 (PRPH2) plays a role in the formation of the
outer segment disc rim, and loss of PRPH2 leads to the absence of outer
segment discs (Cohen, 1983; Goldberg et al., 2016). PRPH2 has also
been suggested to play a role in disc stability and disc shedding
(Edrington et al., 2007; Goldberg et al., 2016). Recently, Salinas et al.
reported that the photoreceptor cilium can release large numbers of
ectosomes (Salinas et al., 2017), similar to the process recently de-
scribed in primary cilia, in which ciliary G protein‒coupled receptors
are dispatched in extracellular signaling‒competent vesicles via actin-
mediated ectocytosis (Nager et al., 2017). PRPH2 maintains this process
at the appropriate level, enabling retained ectosomes to morph into
outer segment discs (Salinas et al., 2017). The formation of PRPH2 is
regulated by the rod outer segment membrane protein-1 (ROM1) pro-
tein, thereby regulating the process of disc internalization (Loewen and
Molday, 2000). The initiation of outer segment disc formation requires
the membrane-bound protein prominin-1 (PROM1), which is localized
to the nascent disc edge (Goldberg et al., 2016). PROM1 also appears to
link outer segment disc rims, thereby helping to stabilize the stack
(Fetter and Corless, 1987). Cadherin-related family member 1 (also
known as protocadherin-21 and encoded by the CDHR1 gene) has also
been implicated in disc rim formation and has been suggested to
function cooperatively with PROM1, as it also resides at the nascent
disc edge (Yang et al., 2008). The photoreceptor-speciﬁc cytosolic
protein RP1 is associated with the ciliary axoneme and is required for
outer segment disc morphogenesis (Liu et al., 2004). Thus, RP1 plays a
role in outer segment disc orientation and has been suggested to serve
as the link between outer segment discs and the axoneme (Liu et al.,
2003). Finally, RP1 has a synergistic interaction with RP1L1, a protein
that has a similar localization pattern and is also required for outer
segment morphogenesis (Yamashita et al., 2009).
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5.5. The interphotoreceptor matrix
The interphotoreceptor matrix ﬁlls the subretinal space, which ex-
tends from the external limiting membrane (i.e., the basal ends of the
Müller cells) to the apical surface of the RPE; the inner and outer seg-
ments of photoreceptor cells are also embedded in this space
(Hollyﬁeld, 1999). For many years, the interphotoreceptor matrix was
believed to simply provide support to the retinal tissue, with no other
signiﬁcant functions. However, we now know that the inter-
photoreceptor matrix plays an important role in many key processes,
including: i) retinal (retinoid) metabolism; ii) retinal adhesion to the
RPE (Hageman et al., 1995; Lazarus and Hageman, 1992; Marmor et al.,
1994; Yao et al., 1994); iii) intercellular communication in terms of
outer segment shedding and phagocytosis by the RPE; iv) matrix turn-
over; v) photoreceptor alignment; vi) growth factor presentation
(Hageman and Johnson, 1991); and vii) regulation of the transport of
oxygen and nutrients to photoreceptor cells (Ishikawa et al., 2015;
Rhodes and Simons, 2007). In addition, this extracellular matrix may
also play a key role in the clinical presentation of progressive retinal
degeneration (Al-Ubaidi et al., 2013).
The interphotoreceptor matrix is composed of proteins and carbo-
hydrates that are secreted by photoreceptors and RPE cells (Kanan
et al., 2009). The principal components of this matrix are proteogly-
cans, hyaluronic acid, collagen and elastin ﬁbers, and other proteins
such as ﬁbronectin, ﬁbrillin, laminins, and ﬁbulins. Hyaluronic acid
polymers form extremely large (100–10,000 kDa) polysaccharides that
interconnect to produce a three-dimensional mesh network (Hollyﬁeld,
1999). This network is connected to Müller cells via CD44 and to the
RPE via proteins containing RHAMM (receptor for hyaluronic acid-
mediated motility)-type binding motifs. In addition, other extracellular
matrix components such as SPACR, SPACRCAN, pigment epithelium-
derived factor (PEDF), and IRBP also contain RHAMM-binding motifs
and are also linked to the hyaluronic acid network (Hollyﬁeld, 1999;
Inatani and Tanihara, 2002).
Three genes (IMPG2, RBP3, and EYS) associated with non-syn-
dromic RP encode proteins that bind to the hyaluronic acid network
(Abd El-Aziz et al., 2008; Bandah-Rozenfeld et al., 2010a; Collin et al.,
2008; den Hollander et al., 2009; Littink et al., 2010; Valverde et al.,
1998; van Huet et al., 2014). SPACRCAN (encoded by the IMPG2 gene)
is a proteoglycan that binds both hyaluronic acid and chondroitin sul-
fate and plays several functional roles, including organizing the inter-
photoreceptor matrix and regulating the growth and maintenance of
the photoreceptor outer segment (Acharya et al., 2000; Foletta et al.,
2001). IRBP (encoded by the RBP3 gene) is the primary soluble protein
in the interphotoreceptor matrix and—as discussed above—plays a role
in the visual cycle (see section 4.2).
In humans, the EYS gene encodes the human ortholog of the
Drosophila eyes shut protein and is one of the largest genes expressed in
the retina. The resulting protein contains several sites for the attach-
ment of glycosaminoglycans side chains; in Drosophila, this protein is an
extracellular protein (Husain et al., 2006; Zelhof et al., 2006). The high
degree of homology between the human and Drosophila orthologs
suggests that the human protein also functions in the extracellular
matrix. In humans, however, this protein, which has four isoforms
(Alfano et al., 2016), can localize to subcellular compartments in the
cytoplasm and to the axoneme of the connecting cilium; moreover,
deleting EYS expression in zebraﬁsh causes mislocalization of outer
segment proteins, suggesting a functional role in ciliary transport (Lu
et al., 2017). In addition, posttranslational modiﬁcations may allow the
protein to target to speciﬁc locations (Alfano et al., 2016). Finally, the
RP1 protein also contains hyaluronic acid‒binding motifs and may in-
teract with the hyaluronic acid scaﬀold if it associates with the pho-
toreceptor's plasma membrane (Hollyﬁeld, 1999).
6. Management of RP
Retinitis pigmentosa can profoundly impact the physical and emo-
tional lives of patients and their families. Therefore, providing adequate
support to patients and their relatives is an essential component in
managing RP. In this chapter, we discuss ophthalmic and genetic
counseling, we describe the current options for genetic testing, we
emphasize the importance of regular visits to the clinic, and we discuss
both current and future therapeutic options.
6.1. Ophthalmic and genetic counseling
A multidisciplinary approach that combines ophthalmic and genetic
counseling services can optimize both the diagnostic process and the
long-term management of RP (Branham and Yashar, 2013). In recent
years, the ﬁeld has witnessed signiﬁcant advances in the methods used
to identify genes. For example, some centers have switched from using
targeted panel sequencing tests for diagnostics and now perform exome
sequencing using a vision-related gene ﬁlter (Haer-Wigman et al.,
2017). In exome sequencing, all coding regions (i.e., exons) within the
entire human genome are sequenced. The addition of a gene ﬁlter
containing all known IRD genes can limit the risk of incidental ﬁndings
in genes that are not necessarily related to the disease. The advantage of
exome sequencing is that if the causative gene is not identiﬁed in any of
the known RP genes, the search can be readily expanded to include
other genes, thereby potentially identifying novel RP-related genes. On
the other hand, exome sequencing is not usually the ﬁrst choice for
obvious cases of X-linked forms of RP. Although mutations in the RPGR
gene account for 70–75% of all patients with an X-linked form of RP,
this gene is not suitable for exome sequencing (Huang et al., 2015),
particularly due to the highly repetitive, purine-rich ORF15 region.
Therefore, this region is better suited to direct sequencing. Currently,
exome sequencing provides a molecular diagnosis in 60–80% of RP
patients (Abu-Saﬁeh et al., 2013; Haer-Wigman et al., 2017); the re-
maining patients likely have a variant that cannot be detected using
exome sequencing, which can include structural rearrangements, mu-
tations in non-coding and/or GC-rich regions, and mutations in genes
that have not yet been associated with retinal dystrophy (Carss et al.,
2017; Nishiguchi et al., 2013). The introduction of whole-genome se-
quencing in routine diagnostics will likely further increase our ability to
obtain molecular diagnoses, although determining the functional role of
many of these putative causative variants will remain a challenge.
Genetic testing often raises a wide range of questions, and patients
are usually referred for genetic counseling, where questions regarding
the reliability of the test results and the implications to the patient and
his/her relatives can be addressed. Performing presymptomatic and/or
predictive testing at too early an age may increase the likelihood of an
unfavorable impact on quality of life; therefore, the ideal age for un-
dergoing genetic testing is currently under debate (Godino et al., 2016).
To help ensure their future autonomy, children rarely undergo pre-
symptomatic testing; however, the availability of new treatment op-
tions, which ideally are applied in the earliest possible stage of the
disease, may warrant testing at a younger age.
Genotyping usually improves the outcome of ophthalmic coun-
seling; however, the number of well described phenotypes for a given
genetic subtype is usually limited, and the phenotypes can vary widely
within a subtype and even between family members who share iden-
tical mutations. Nevertheless, the information discussed in Chapter 4
can provide the clinician with an overview of the clinical aspects as-
sociated with the various genetic subtypes. For example, central visual
function often deteriorates rapidly in RP patients with a mutation in the
CERKL gene, whereas visual acuity is generally preserved much longer
in RP patients with a mutation in the TOPORS gene. Therefore,
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understanding the underlying genetic proﬁle and other modiﬁers that
can inﬂuence the phenotype will help provide a more reliable clinical
prognosis. In anticipation of such an in-depth genetic analysis, thor-
ough follow-up examinations that include visual ﬁeld analysis, SD-OCT,
and FAF will serve to monitor the clinical progression of the retinal
dystrophy, as well as to predict the decline in visual function. In ad-
dition, other ocular pathologies such as cataract and CME may also be
identiﬁed at an early stage and treated accordingly.
6.2. Visual rehabilitation
In recent years, visual rehabilitation for RP patients with low visual
acuity has evolved into a multidisciplinary approach that focuses on the
patient's functional abilities and needs (Herse, 2005), thereby providing
high value to patients with RP. Vision rehabilitation centers provide
support and training, including orientation and mobility training
combined with low-vision aids such as ﬂashlights, night-vision goggles,
and/or reverse telescopes in order to optimize residual visual function.
In advanced disease, the patient's independence and functional quality
of life can be improved using text-to-speech software to allow the pa-
tient to interpret text, and a guide dog can further increase the patient's
mobility and independence. However, the social impact of the gradual
deterioration of the visual ﬁeld should not be underestimated.
6.3. Treatment of associated ocular abnormalities
The visual gain realized following cataract surgery in RP patients
depends largely on the amount of residual macular function. The like-
lihood of visual recovery is highest in RP patients who have an in-
tact—or only slightly disrupted—foveal ellipsoid zone (Nakamura
et al., 2015; Yoshida et al., 2015a).
Some reports indicate that RP patients may have an increased risk of
developing complications during and following cataract surgery; these
complications can include zonular insuﬃciency (in 19% of cases)
(Dikopf et al., 2013), posterior capsular opaciﬁcation (44–95% of cases)
(Bayyoud et al., 2013; De Rojas et al., 2017; Yoshida et al., 2015a), and
anterior capsule contraction (10–38% of cases) (Hayashi et al., 1998;
Jackson et al., 2001; Yoshida et al., 2015a). Although the scientiﬁc
evidence is absent, some surgeons report a more severe post-operative
inﬂammation in RP patients. In general, pre-operative treatment with
steroids may be useful in patients with RP to prevent this inﬂammation
as well as CME. There is currently no indication that surgery accelerates
the progression of RP (De Rojas et al., 2017). On the other hand, the
subjective visual gain following cataract surgery in RP patients is often
considerable. Therefore, cataract extraction should be seriously con-
sidered in visually signiﬁcant cataracts, even in the presence of ad-
vanced RP.
To date, no large randomized controlled clinical trial has been
performed to evaluate the eﬀect of treating CME in RP patients. The
treatment of choice for CME is carbonic anhydrase inhibitors (Strong
et al., 2017). A meta-analysis conducted by Huang et al. showed a mean
reduction in central retinal thickness of 46% (Huang et al., 2017b).
However, often there is no correlation between anatomical and func-
tional improvement (Huang et al., 2017b). Prescribed dosages for oral
acetazolamide vary between 125 and 500mg daily, and topical car-
bonic anhydrase inhibitors like 1–2% dorzolamide or brinzolamide are
typically administered three times a day. Since the optimal therapeutic
dose for the individual is still unknown, a trial and error approach is
advised. Recurrence of CME can occur after cessation of carbonic an-
hydrase inhibitor treatment (Huang et al., 2017b), and eﬃcacy may
diminish during prolonged treatment (Huckfeldt and Comander, 2017).
Retreatment with carbonic anhydrase inhibitors after a period of dis-
continued use, may again have a favorable eﬀect (Thobani and
Fishman, 2011). Refractory CME can be treated with intravitreal ster-
oids (Huckfeldt and Comander, 2017). The use of intravitreal anti-VEGF
(vascular endothelial growth factor) in RP patients remains unclear, as
studies do not agree with respect to the beneﬁcial eﬀects; moreover,
VEGF levels are markedly lower in the aqueous humor of RP patients
(Strong et al., 2017). It is important to note that the amount of CME can
ﬂuctuate over time—particularly in children—even without interven-
tion; this should be taken into account during treatment (Huckfeldt and
Comander, 2017).
Although epiretinal membranes are prevalent among RP patients,
few reports address the eﬀects of membrane peeling in RP patients.
Ikeda et al. reported morphological improvement following epiretinal
membrane peeling in 9 out of 11 eyes, although only three of these
eyes—two of which underwent concomitant cataract extraction sur-
gery—had long-term improvement in visual acuity (Ikeda et al., 2015).
This relatively limited rate of success, together with the potential
toxicity associated with direct intraocular illumination, suggests that
epiretinal membrane peeling should be used with caution in patients
with RP.
6.4. Treatment options for RP
Signiﬁcant advances in our knowledge regarding the genetic causes
of RP have been paralleled by signiﬁcant progress in the development
of novel strategies for treating this disease (Scholl et al., 2016). These
strategies can be subdivided into two general categories: i) approaches
that are gene-speciﬁc or even mutation-speciﬁc, and ii) approaches that
exert a therapeutic eﬀect independent of the underlying genetic defect.
Below, we discuss the main features of the various therapeutic ap-
proaches, including their potential advantages and limitations with
respect to treating patients with RP.
6.4.1. Gene-speciﬁc and mutation-speciﬁc approaches
The majority of genes mutated in RP encode proteins that are ex-
pressed either in photoreceptor cells or in the RPE. Therefore, to be
eﬀective, gene-speciﬁc and/or mutation-speciﬁc approaches require the
presence of the cells that will be targeted; as a result, these approaches
are most successful in the early stages of the disease, before cell de-
generation. With gene augmentation therapy‒based approaches, a
construct driving the expression of a wild-type copy of the cDNA cor-
responding to the mutated gene is introduced into the target cells, with
the goal of restoring wild-type expression in these cells. In the case of
RP and allied diseases, virus-based vectors such as adeno-associated
viruses (AAVs) are often used to deliver the genetic cargo to target cells
in the retina; the virus is usually administered via intravitreal or sub-
retinal injection. In 2008, the ﬁrst studies to test the safety and eﬃcacy
of using RPE65 gene augmentation therapy in patients with LCA or
early-onset RP due to bi-allelic RPE65 mutations were reported
(Bainbridge et al., 2008; Hauswirth et al., 2008; Maguire et al., 2008).
The promising results obtained from these studies provided an en-
ormous boost to the ﬁeld and led to phase I/II clinical trials designed to
test gene therapy‒based approaches for treating several other genetic
subtypes of retinal disease, including choroideremia (MacLaren et al.,
2014), MERTK-associated RP (Ghazi et al., 2016), and—more re-
cently—CNGA3-associated achromatopsia, PDE6A-associated RP,
RPGR-associated X-linked RP, retinoschisis, and Stargardt disease (see
www.clinicaltrials.gov). The recent phase 3 study in patients with a
RPE65-mediated inherited retinal dystrophy who were treated with
voretigene neparvovec, conﬁrmed treatment safety and eﬃcacy; pa-
tients showed improved light sensitivity, visual ﬁelds and navigational
ability under dim light conditions (Russell et al., 2017). Subsequently,
this led to the ﬁrst US FDA approved gene therapy for retinal disease.
Despite these initial advances, however, important challenges must be
overcome before gene augmentation therapy can be widely im-
plemented. For example, it is unclear whether one-time administration
of a therapeutic vector can provide long-term, long-lasting clinical
beneﬁts. The cargo capacity of the most commonly used viral vectors is
also relatively limited and is therefore not suitable for delivering the
large cDNAs corresponding to several of the genes that are mutated in
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many patients with RP (for example, the EYS and USH2A genes). Other
challenges include controlled expression levels, dominant-negative
mechanisms, the relative small number of patients for the genetic
subtypes as well as the ﬁnancial costs of the highly individualized forms
of treatment.
Other emerging therapeutic strategies involve antisense oligonu-
cleotides (AONs), which are small, versatile RNA molecules that can
modify pre-mRNA splicing by speciﬁcally binding to a target region in
the pre-mRNA, thereby suppressing aberrant splicing events caused by
certain mutations (Collin and Garanto, 2017), and genome editing, for
example using the CRISPR/Cas9 system. This latter technique in-
troduces a highly precise double-strand break in the genomic DNA at
the site of the mutation, and can be used to repair a primary genetic
defect directly within the patient's genome (Yanik et al., 2017).
Another class of highly versatile therapeutic compounds that can act
in a gene-speciﬁc and/or mutation-speciﬁc manner are the small-mo-
lecule compounds. In early-onset retinal degeneration in patients with a
mutation in the LRAT or RPE65 gene, the visual cycle—in which all-
trans-retinal is converted back into 11-cis-retinal via several enzymatic
reactions—is disrupted. Oral treatment with 9-cis-retinoid, an analog of
11-cis-retinal, was well tolerated and moderately eﬀective in early-
phase clinical trials in patients with a mutation in the aforementioned
genes; moreover, treatment eﬃcacy was correlated with residual retinal
integrity (Scholl et al., 2015).
Although beyond the scope of this review, it is important to note
that diet-based treatment can prevent or reduce disease progression in
the following three syndromic forms of RP: adult Refsum disease,
Bassen-Kornzweig syndrome, and α-tocopherol transfer protein deﬁ-
ciency (also known as familial isolated vitamin E deﬁciency).
6.4.2. Mutation-independent approaches
In recent years, several dietary changes and dietary supplements
(e.g., vitamin A) have been recommended for the treatment of RP
(Brito-Garcia et al., 2017). However, a Cochrane systematic review
conducted by Rayapudi et al. (2013) found no clear evidence that vi-
tamin A and/or the ﬁsh oil docosahexaenoic acid has beneﬁcial eﬀects
in RP patients in general.
Cell replacement therapy is the administration of ocular-derived
retinal progenitor cells (RPCs) or non‒ocular-derived stem cells such as
embryotic stem cells (ESCs) and induced pluripotent stem cells (iPSCs)
into the vitreous body or subretinal space. Each of these cell types has
speciﬁc advantages and disadvantages (Tang et al., 2017). For example,
RPCs are relatively easy to process, and the recipient does not require
immunosuppression therapy; however, obtaining suﬃcient donor cells
is problematic. In contrast, stem cells require a more extensive manu-
facturing process. The key diﬀerence between ESCs and iPSCs is that
iPSCs can be derived from the patient, thereby allowing the autologous
transplantation of iPSC-derived RPE or photoreceptor cells, thus
avoiding immunosuppressive treatment; moreover, the underlying ge-
netic defect can even be corrected prior to transplantation using
genome editing (Li et al., 2016). However, such highly individualized
treatments are associated with extremely high costs. Therefore, options
for using human leukocyte antigen (HLA)-matched iPSCs from a data-
bank are receiving increasing attention (Chakradhar, 2016; de Rham
and Villard, 2014). Various transplantation approaches are currently
used, including transplantation of stem cell‒derived RPE cells and/or
photoreceptor cells (Seiler and Aramant, 2012). Phase I/II trials using
RPCs are currently being performed in RP patients in order to assess the
in vivo safety, long-term survival, and function of the graft (see www.
clinicaltrials.gov). Although clinical applications are still in their in-
fancy, stem/progenitor cell‒based therapeutic approaches represent a
promising future for patients with advanced RP.
Another emerging approach is the use of electronic retinal implants
for end-stage RP patients with little or no light perception. Two retinal
implants are currently available on the market. The Argus II epiretinal
implant (produced by Second Sight Medical Products Inc. in Sylmar,
CA) has received both European CE certiﬁcation and US FDA approval,
and the Alpha AMS subretinal implant (produced by Retina Implant AG
in Reutlingen, Germany) has received CE certiﬁcation (Mills et al.,
2017). Both of these implants function by stimulating the inner retinal
layers and therefore require an intact inner retinal architecture. An
epiretinal implant is connected to a miniature camera mounted on
eyeglasses; the implant then stimulates the residual retinal ganglion
cells directly. In contrast, a subretinal implant consists of a light-sen-
sitive micro-photodiode array that stimulates the bipolar cell layer.
Retinal implants can restore basic visual function, improve performance
in vision-related tests, and increase the daily mobility of patients with
RP (da Cruz et al., 2016; Stingl et al., 2017; Zrenner et al., 2011). For
example, improvement in visual acuity from light perception without
projection to 20/546 was recently reported in a patient who received an
Alpha AMS implant (Stingl et al., 2017). Despite these promising re-
sults, visual rehabilitation for patients with these prostheses is complex,
and several challenges must still be overcome, including adverse ef-
fects, device longevity, and resolution (Cheng et al., 2017; Zrenner,
2013).
Yet another relatively new approach that can provide therapeutic
beneﬁts in patients who have lost photoreceptor and/or RPE cells is
optogenetics, which uses gene therapy to express light-activated ion
channels in the residual retinal neurons, thereby restoring photo-
sensitivity (Busskamp et al., 2012). Despite promising results in both
cell-based models and animal models, the true potential of this ap-
proach needs to be tested fully in a clinical setting.
Finally, several neuroprotective factors have been shown to slow
photoreceptor loss in numerous animal models, including brain-derived
neurotrophic factor (BDNF) (Okoye et al., 2003), basic ﬁbroblast
growth factor (bFGF) (Faktorovich et al., 1990), ciliary neurotrophic
factor (CNTF) (Liang et al., 2001), glial cell‒derived neurotrophic
factor (GDNF) (Dalkara et al., 2011), nerve growth factor (NGF) (Lenzi
et al., 2005), and rod-derived cone viability factor (rdCVF) (Byrne et al.,
2015). However, there is currently no evidence that these compounds
are beneﬁcial in treating RP (Birch et al., 2016). Transcorneal electrical
stimulation (TES), a novel therapeutic approach for retina disease and
optic neuropathy, also seems to exert its eﬀect through the release of
neurotrophic factors after corneal electrostimulation. Proof of principle
of TES has been established in animal models (Morimoto et al., 2007)
and treatment appears to be safe in patients (Schatz et al., 2011, 2017;
Wagner et al., 2017), although larger studies are needed to provide
treatment eﬃcacy over a prolonged time.
7. Conclusions
In this review, we provided an overview of the clinical character-
istics of RP in general, as well as the speciﬁc features of genetically
deﬁned RP subtypes. This information can help the clinician identify
the clinical RP entity and better predict the disease course, ultimately
providing the patient with the best possible information regarding
prognosis. In addition, we discussed the main pathways aﬀected in RP,
as well as the location and function of the proteins involved, thereby
revealing high genetic and clinical similarity between RP and other
IRDs, including LCA and cone-rod dystrophies. Together, these dis-
orders are currently considered to represent a continuum of retinal
dystrophies with signiﬁcant clinical and genetic overlap.
Our rapidly increasing knowledge of aﬀected biological pathways
has shifted attention to the individual genetic subtypes of RP. This is
paralleled by various treatment strategies exploring the applications of
gene and cell-based therapies, retinal implants or transplantation. The
nature of the genetic defect, the resulting molecular pathogenesis and
the extent of the degeneration will determine which therapeutic mod-
ality will be the most appropriate in the individual RP patient.
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